In a phase I dose-escalation study involving FRα-positive solid tumors, MORAb-202 achieved a disease control rate of 75%, with one complete response and two partial responses among nine ovarian cancer patients [67]. This evidence concerns the gene FOLR1 and ovarian carcinoma.